Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | The future of transdermal estradiol in managing prostate cancer

Duncan Gilbert • 16 Sep 2024
ESMO 2024
Genitourinary Cancer Prostate Cancer

Duncan Gilbert, MA, MRCP, FRCR, PhD, University College London, London, UK, explores the potential of transdermal estradiol as a viable alternative to LH-RG analogs for androgen deprivation therapy in men with prostate cancer. The key benefits of transdermal estradiol include reduced hot flushes and improved long-term bone health, while noting that transdermal estradiol patches are not yet licensed for this indication. With positive oncological outcomes, there is hope for future integration within the NHS, providing men with prostate cancer an additional treatment option. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Duncan Gilbert

Improving long-term quality of life in prostate cancer treatment
1:07
Improving long-term quality of life in prostate cancer treatment
Duncan Gilbert • 16 Sep 2024
Estrogen patches as a safer androgen suppression alternative in prostate cancer
2:00
Estrogen patches as a safer androgen suppression alternative in prostate cancer
Duncan Gilbert • 16 Sep 2024
Transdermal estradiol for androgen suppression in locally advanced prostate cancer
1:10
Transdermal estradiol for androgen suppression in locally advanced prostate cancer
Duncan Gilbert • 16 Sep 2024
PATCH: transdermal estradiol versus LH-RH analogues in prostate cancer
1:29
PATCH: transdermal estradiol versus LH-RH analogues in prostate cancer
Duncan Gilbert • 16 Sep 2024

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals